12/1/2022 – Awakn Life Sciences Announces Signing of Lease for Second Clinic in Norway

11/23/2022 – Awakn Life Sciences Announces Location for Larger Oslo Clinic

11/9/2022 – Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York

10/25/2022 – Awakn Life Sciences Secures Funding to Expand Nordic Commercial Operations

9/15/2022 – Awakn Life Sciences Reports Strong Q2 2022 Results

9/12/2022 – Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis(R) Technology (An Orally Disintegrating Tablet) to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program